Anti-Rheumatic Drugs - Ecuador | Statista Market Forecast

In Ecuador, the revenue in the Anti-Rheumatic Drugs market is estimated to reach US$19.44m by 2024.
It is expected to experience an annual growth rate (CAGR 2024-2029) of 0.67%, leading to a market volume of US$20.10m by 2029.
When compared globally, United States is projected to generate the highest revenue in this market, amounting to US$34.70bn in 2024.
Ecuador's market for anti-rheumatic drugs is experiencing a growing demand due to the increasing prevalence of rheumatic diseases in the country.

Definition:
The market Anti-Rheumatic Drugs includes medication for the treatment of the inflammatory disease rheumatism. Due to the high prevalence of rheumatism and the large size of the market, this section of immune diseases is treated as a separate market. Both steroidal and non-steroidal anti-rheumatics are included. Disease-modifying rheumatic drugs (DMARDs), such as tumor necrosis factor inhibitors (a type of biologic DMARD), are particularly important in terms of commerciality.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: AbbVie, Johnson & Johnson, Pfizer, Amgen, Roche

Drugs to treat rheumatism
Steroidal (corticosteroids) and non-steroidal anti-rheumatics
Disease-modifying antirheumatic drugs (DMARDs)
Tumor necrosis factor (TNF) inhibitors

Drugs to treat other autoimmune diseases (such as multiple sclerosis or psoriasis)
Analgetics for general use (such as paracetamol)
Treatment of osteoarthritis

The demand for Anti-Rheumatic Drugs in Ecuador has been increasing steadily over the years.

Customer preferences: Ecuador has a high prevalence of rheumatoid arthritis, which has led to a high demand for Anti-Rheumatic Drugs. Patients in Ecuador prefer to use biologic drugs, which are more effective in treating rheumatoid arthritis than traditional disease-modifying anti-rheumatic drugs (DMARDs). The preference for biologic drugs is due to their ability to reduce inflammation and slow down joint damage.

Trends in the market: The market for Anti-Rheumatic Drugs in Ecuador has been growing due to the increasing prevalence of rheumatoid arthritis. The introduction of biologic drugs has also contributed to the growth of the market. The market for biologic drugs is expected to grow in the coming years due to their effectiveness in treating rheumatoid arthritis. However, the high cost of biologic drugs is a major challenge for patients in Ecuador. This has led to the development of biosimilars, which are cheaper versions of biologic drugs.

Local special circumstances: Ecuador has a high prevalence of rheumatoid arthritis, which has led to a high demand for Anti-Rheumatic Drugs. The government of Ecuador has implemented policies to increase access to healthcare, which has led to an increase in the number of patients seeking treatment for rheumatoid arthritis. The government has also implemented policies to reduce the cost of healthcare, which has led to the development of biosimilars.

Underlying macroeconomic factors: The economy of Ecuador has been growing steadily over the years, which has led to an increase in the demand for healthcare services. The government of Ecuador has implemented policies to increase access to healthcare, which has led to an increase in the number of patients seeking treatment for rheumatoid arthritis. The high prevalence of rheumatoid arthritis in Ecuador has also contributed to the growth of the market for Anti-Rheumatic Drugs. The introduction of biosimilars has made treatment more affordable for patients in Ecuador.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.